MARKET

CTOR

CTOR

Citius Oncology, Inc.
NASDAQ
1.050
-0.080
-7.08%
After Hours: 1.040 -0.01 -0.94% 19:50 12/15 EST
OPEN
1.130
PREV CLOSE
1.130
HIGH
1.170
LOW
1.030
VOLUME
424.48K
TURNOVER
--
52 WEEK HIGH
6.19
52 WEEK LOW
0.5506
MARKET CAP
89.04M
P/E (TTM)
-3.8016
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CTOR last week (1208-1212)?
Weekly Report · 1d ago
Citius Oncology Raises $18M Through Direct Offering
TipRanks · 5d ago
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Barchart · 6d ago
Citius Oncology added to the Russell Microcap Index
Seeking Alpha · 12/09 15:57
Citius Oncology announces $18 million registered direct offering
Seeking Alpha · 12/09 13:49
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
TipRanks · 12/09 13:35
Press Release: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
Dow Jones · 12/09 13:30
Press Release: Citius Oncology Announces $18 -2-
Dow Jones · 12/09 13:30
More
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.

Webull offers Citius Oncology Inc stock information, including NASDAQ: CTOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CTOR stock methods without spending real money on the virtual paper trading platform.